Avalyn Pharma (NASDAQ:AVLN) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen cut shares of Avalyn Pharma (NASDAQ:AVLN) from a hold rating to a sell rating in a research report sent to investors on Saturday morning.

A number of other equities analysts have also recently commented on the stock. Morgan Stanley lifted their price target on shares of Avalyn Pharma from $53.00 to $57.00 and gave the stock an “overweight” rating in a research note on Thursday. Weiss Ratings initiated coverage on shares of Avalyn Pharma in a report on Thursday. They set a “sell (d+)” rating on the stock. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research note on Wednesday, May 27th. Jefferies Financial Group initiated coverage on Avalyn Pharma in a research report on Monday, May 25th. They set a “buy” rating and a $52.00 target price for the company. Finally, Guggenheim began coverage on Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $60.00.

Avalyn Pharma Stock Performance

NASDAQ:AVLN opened at $39.25 on Friday. The firm’s fifty day moving average is $30.15. Avalyn Pharma has a fifty-two week low of $24.15 and a fifty-two week high of $39.99. The stock has a market cap of $1.74 billion and a price-to-earnings ratio of -1.80. The company has a quick ratio of 11.03, a current ratio of 33.12 and a debt-to-equity ratio of 0.04.

Avalyn Pharma (NASDAQ:AVLN) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.05. Equities analysts forecast that Avalyn Pharma will post -3.81 EPS for the current year.

Institutional Investors Weigh In On Avalyn Pharma

An institutional investor recently bought a new stake in Avalyn Pharma stock. Bank of New York Mellon Corp bought a new position in Avalyn Pharma Inc. (NASDAQ:AVLN) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 40,140 shares of the company’s stock, valued at approximately $1,321,000. Bank of New York Mellon Corp owned approximately 0.09% of Avalyn Pharma at the end of the most recent reporting period.

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.